Modafinil – Kodiac biolabs

Plain-language summaryIntrigue 80 / 100

Modafinil is the world’s most prescribed wakefulness-promoting medication, sold as Provigil. It is FDA-approved for narcolepsy and shift work disorder. Off-label use for fatigue and cognitive enhancement is widespread. The mechanism involves dopamine transporter binding plus downstream histamine and orexin activation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundFederally scheduled

60/100

Approved Schedule IV eugeroic with a genuinely contested mechanism that keeps it more alive as a research probe than its age suggests

Look, modafinil is interesting in the specific way a 25-year-old approved drug can still be interesting: the mechanism is genuinely not fully settled, and that keeps it more alive as a research object than its history would suggest.

The DAT inhibition story is real, but the affinity numbers tell a strange tale. A Ki around 4 microM is surprisingly weak for the magnitude of wakefulness effect you see clinically. That gap is what keeps researchers digging. The downstream orexinergic cascade, histamine elevation in the tuberomammillary nucleus, glutamatergic bias in the prefrontal cortex: these are all real pharmacological events, but the primary trigger is still debated. Some groups argue NET inhibition contributes more than the DAT story acknowledges. Others point to non-transporter targets entirely. Thats not a knock on modafinil; its actually the source of its continued bench value as a probe for wakefulness circuitry rather than a clean single-receptor tool.

The differentiation score reflects that modafinil defines its category. The profile is genuinely distinct from amphetamines: no steep dopamine release kinetics, no meaningful peripheral sympathomimetic load at typical research concentrations, softer abuse liability. Armodafinil, the R-enantiomer, is the cleaner modern form and increasingly preferred in new programs, but modafinil as the racemic parent is better represented in the existing literature and remains the standard comparator for the eugeroic class.

Evidence quality is one of modafinil’s stronger suits, and honestly the most straightforward thing about it. Multiple well-controlled RCTs in narcolepsy and shift work disorder, FDA approval going back to 1998, decades of follow-on mechanistic work across independent groups. The weak link is the cognitive enhancement literature in healthy subjects, where effect sizes are small and replication is inconsistent. If your research question touches a diagnosed wakefulness disorder, the evidence base is mature and usable. If you’re studying it as a general cognitive enhancer in healthy populations, the numbers will disappoint you.

From a pure bench perspective, modafinil has real value as a pharmacological probe for DAT-adjacent circuitry and orexin biology. The low affinity and complex selectivity profile that make it mechanistically murky are precisely what make it useful for studying network-level wakefulness rather than receptor-level dissections. Investigators working on shift work physiology, fatigue models, or orexin-deficient animal preparations reach for it as a reference compound.

We rate it 60. The Schedule IV ceiling sits at 75 but doesn’t bind here; modafinil earns this position on its own terms. It’s a well-characterized, genuinely useful research compound held back by age, modest and inconsistent off-label effect sizes, and the fact that armodafinil has largely eclipsed it in new program design.

Novelty: 28
Mechanism promise: 62
In-category differentiation: 65
Evidence quality: 78
Translational signal: 72
Research bench value: 65

Rationale Modafinil scores on the strength of its multi-target wakefulness mechanism, a strong clinical evidence base in approved indications, and real bench utility as a DAT/orexin probe; novelty is dragged down by 25 years of literature and armodafinil’s encroachment. The Schedule IV cap of 75 does not bind; a natural score of 60 reflects a well-characterized but aging compound whose mechanism debate is the most interesting thing about it.

Eugeroic / wakefulness-promoting agent

A benzhydryl sulfinyl acetamide approved for narcolepsy and shift work disorder, characterized by selective dopamine transporter binding and downstream histaminergic activation.

Abstract

Modafinil (CAS 68693-11-8; molecular formula C15H15NO2S; molecular weight 273.35) is a wakefulness-promoting agent first synthesized at Laboratoire Lafon in France in the 1970s as the active metabolite of adrafinil and approved by the FDA in 1998 for excessive daytime sleepiness associated with narcolepsy, shift work sleep disorder, and obstructive sleep apnea. The compound is a racemic mixture; the (R)-enantiomer (armodafinil) carries the majority of the wakefulness-promoting activity and is marketed separately. The principal mechanism is binding to the dopamine transporter (DAT) with weak inhibitor affinity (Ki approximately 4 microM), producing modest extracellular dopamine elevation in the striatum and prefrontal cortex without the steep release kinetics characteristic of amphetamines or methylphenidate. Downstream effects include activation of orexinergic neurons in the lateral hypothalamus, elevation of histamine in the tuberomammillary nucleus, and increased glutamatergic tone in the prefrontal cortex with concurrent attenuation of GABAergic inhibition. The plasma half-life is 12 to 15 hours; oral bioavailability is high (greater than 80 percent); metabolism is hepatic via CYP3A4 and to a lesser extent via amide hydrolysis. Clinical efficacy in narcolepsy and shift work indications is well established; off-label use for cognitive enhancement in healthy individuals is widespread but the magnitude of cognitive benefit in healthy subjects is small and inconsistent across trials. Schedule IV in the United States. Common adverse events include headache, nausea, anxiety, and insomnia; rare serious events include Stevens-Johnson syndrome and DRESS. The compound is not a controlled substance under international treaty but is regulated nationally in most jurisdictions.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-016Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.